应用HER2基因表达评估HER2阳性乳腺癌的靶向治疗效果的研究进展  

Research progress of HER2 gene expression in evaluating targeted therapy effect for patients with HER2-positive breast cancer

作　　者：路晓阳 冯景[1] 周毅[1] LU Xiaoyang;FENG Jing;ZHOU Yi(Department of Breast Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,P.R.China)

机构地区：[1]哈尔滨医科大学附属第一医院乳腺外科,哈尔滨150001

出　　处：《中国普外基础与临床杂志》2022年第5期683-687,共5页Chinese Journal of Bases and Clinics In General Surgery

基　　金：黑龙江省自然科学基金项目(项目编号:YQ2020H012)。

摘　　要：目的总结人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)基因表达与HER2阳性乳腺癌靶向治疗效果的关系并总结HER2基因拷贝数相关研究的新进展。方法复习近年来关于HER2阳性乳腺癌与相关靶向治疗的文献并进行综述。结果HER2基因拷贝数和HER2/17号染色体着丝粒区(centromere on chromosome 17,CEP17)比值与HER2阳性乳腺癌的预后有关,且循环肿瘤DNA测序有望成为靶向治疗效果的预测指标。结论较高的H E R 2基因拷贝数可能与H E R 2阳性乳腺癌较好的预后相关,HER2/CEP17比值和循环肿瘤DNA对有效评估HER2阳性乳腺癌患者对曲妥珠单抗治疗的反应性具有一定意义。Objective To summarize the correlation between human epidermal growth factor receptor 2(HER2)gene expression and the efficacy of targeted therapy for patients with HER2-positive breast cancer,and to summarize the new progress in the study of HER2 gene copy number.Method The relevant literatures on researches of targeted therapy effectiveness for patients with HER2-positive breast cancer were retrieved and reviewed.Results HER2 gene copy number and HER2/centromere on chromosome 17(CEP17)ratio were related to the prognosis of patients with HER2-positive breast cancer,and circulating tumor DNA sequencing was expected to be a predictive indicator of targeted therapy effectiveness.Conclusion Higher copy number of HER2 gene might be associated with a better prognosis of HER2-positive breast cancer,and HER2/CEP17 ratio and circulating tumour DNA are of some significances in evaluating treatment response of trastuzumab for patients with HER2-positive breast cancer.

关 键 词：人类表皮生长因子受体2 拷贝数 曲妥珠单抗 循环肿瘤DNA 

分 类 号：R737.9[医药卫生—肿瘤]